chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Sex: U
Vaccine: COVID19, COVID19
Symptoms: Condition aggravated, Fatigue, Vaccination site pain
Clinical narrative: sore injection site arms; felt slightly fatigued; This spontaneous case was reported by a patient family member or friend and describes the occurrence of VACCINATION SITE PAIN (sore injection site arms) and FATIGUE (felt slightly fatigued) in an adult patient of an unknown gender who received mRNA-1273 (Spikevax) (batch no. 001B21A) for COVID-19 prophylaxis.     Previously administered products included for Product used for unknown indication: Flu Vaccine and Flu Vaccine. Past adverse reactions to the above products included Fatigue with Flu Vaccine; and Vaccination site pain with Flu Vaccine.   On an unknown date, the patient received first dose of mRNA-1273 (Spikevax) (Intramuscular) 1 dosage form. On an unknown date, received second dose of mRNA-1273 (Spikevax) (unknown route) dosage was changed to 1 dosage form, third dose of mRNA-1273 (Spikevax) (unknown route) dosage was changed to 1 dosage form, fourth dose of mRNA-1273 (Spikevax) (unknown route) dosage was changed to 1 dosage form and fifth dose of mRNA-1273 (Spikevax) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE PAIN (sore injection site arms) and FATIGUE (felt slightly fatigued). At the time of the report, VACCINATION SITE PAIN (sore injection site arms) and FATIGUE (felt slightly fatigued) had resolved.        The action taken with mRNA-1273 (Spikevax) (Unknown) and mRNA-1273 (Spikevax) (Intramuscular) was unknown.   For mRNA-1273 (Spikevax) (Intramuscular), the reporter did not provide any causality assessments.   No relevant concomitant medications were reported.   The patient reports that she and her siblings each received 5 Moderna vaccinations and that they love Moderna The patient then goes on to say that she and her siblings had no side effects to the Moderna vaccine except they had sore injection site arms and felt slightly fatigued. Just like with a Flu Shot. Arm was sore for a day.  No treatment information was provided.   This case was linked to US-MODERNATX, INC.-MOD-2023-710705 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-710705:1 out of 5 siblings
Sex: U
Vaccine: COVID19, COVID19
Symptoms: Intercepted medication error, No adverse event, Product storage error, Product temperature excursion issue
Clinical narrative: Excursion began on 30Jan and experienced several excursions until 14Feb2023; No Adverse Event; Excursion began on 30Jan and experienced several excursions until 14Feb2023; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (Excursion began on 30Jan and experienced several excursions until 14Feb2023), POOR QUALITY PRODUCT ADMINISTERED (Excursion began on 30Jan and experienced several excursions until 14Feb2023) and NO ADVERSE EVENT (No Adverse Event) in an adult patient of an unknown gender who received mRNA-1273 (Spikevax) (batch no. 060B22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 01-Feb-2023, the patient received dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On 01-Feb-2023, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Excursion began on 30Jan and experienced several excursions until 14Feb2023). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Excursion began on 30Jan and experienced several excursions until 14Feb2023) and NO ADVERSE EVENT (No Adverse Event). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (Excursion began on 30Jan and experienced several excursions until 14Feb2023), POOR QUALITY PRODUCT ADMINISTERED (Excursion began on 30Jan and experienced several excursions until 14Feb2023) and NO ADVERSE EVENT (No Adverse Event) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter considered NO ADVERSE EVENT (No Adverse Event) to be not related. No further causality assessments were provided for PRODUCT TEMPERATURE EXCURSION ISSUE (Excursion began on 30Jan and experienced several excursions until 14Feb2023) and POOR QUALITY PRODUCT ADMINISTERED (Excursion began on 30Jan and experienced several excursions until 14Feb2023).    No concomitant medications were reported. It was reported that time excursion duration was 90 minutes maximum temperature was minus 4C. No treatment medications were reported.   This case was linked to US-MODERNATX, INC.-MOD-2023-710558, US-MODERNATX, INC.-MOD-2023-710848, US-MODERNATX, INC.-MOD-2023-710849 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-710558:Master case US-MODERNATX, INC.-MOD-2023-710848: US-MODERNATX, INC.-MOD-2023-710849:
Sex: U
Vaccine: COVID19, COVID19
Symptoms: No adverse event, Poor quality product administered, Product storage error
Clinical narrative: Excursion began on 30Jan and experienced several excursions until 14Feb2023; No Adverse Event; Excursion began on 30Jan and experienced several excursions until 14Feb2023; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (Excursion began on 30Jan and experienced several excursions until 14Feb2023), POOR QUALITY PRODUCT ADMINISTERED (Excursion began on 30Jan and experienced several excursions until 14Feb2023) and NO ADVERSE EVENT (No Adverse Event) in an adult patient of an unknown gender who received mRNA-1273 (Spikevax) (batch no. 060B22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 01-Feb-2023, the patient received dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On 01-Feb-2023, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Excursion began on 30Jan and experienced several excursions until 14Feb2023). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Excursion began on 30Jan and experienced several excursions until 14Feb2023) and NO ADVERSE EVENT (No Adverse Event). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (Excursion began on 30Jan and experienced several excursions until 14Feb2023), POOR QUALITY PRODUCT ADMINISTERED (Excursion began on 30Jan and experienced several excursions until 14Feb2023) and NO ADVERSE EVENT (No Adverse Event) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter considered NO ADVERSE EVENT (No Adverse Event) to be not related. No further causality assessments were provided for PRODUCT TEMPERATURE EXCURSION ISSUE (Excursion began on 30Jan and experienced several excursions until 14Feb2023) and POOR QUALITY PRODUCT ADMINISTERED (Excursion began on 30Jan and experienced several excursions until 14Feb2023).    No concomitant medications were reported. It was reported that time excursion duration was 90 minutes maximum temperature was minus 4C. No treatment medications were reported.   This case was linked to US-MODERNATX, INC.-MOD-2023-710558, US-MODERNATX, INC.-MOD-2023-710848, US-MODERNATX, INC.-MOD-2023-710849 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-710558:Master case US-MODERNATX, INC.-MOD-2023-710848: US-MODERNATX, INC.-MOD-2023-710849:
Sex: U
Vaccine: COVID19
Symptoms: Expired product administered, No adverse event, Product storage error
Clinical narrative: Product storage error; No adverse event; 14 of February around 10 o'clock AM which was administered expired February 13, 2023; This spontaneous case was reported by a consumer and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (14 of February around 10 o'clock AM which was administered expired February 13, 2023), PRODUCT STORAGE ERROR (Product storage error) and NO ADVERSE EVENT (No adverse event) in a child patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. AS1414B) for COVID-19 prophylaxis.     It was reported that patient had not received any other vaccines in the 4 weeks prior to COVID-19 vaccine.     On 14-Feb-2023 at 10:00 AM, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 14-Feb-2023 at 10:00 AM,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced EXPIRED PRODUCT ADMINISTERED (14 of February around 10 o'clock AM which was administered expired February 13, 2023). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Product storage error) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (14 of February around 10 o'clock AM which was administered expired February 13, 2023), PRODUCT STORAGE ERROR (Product storage error) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (14 of February around 10 o'clock AM which was administered expired February 13, 2023) and PRODUCT STORAGE ERROR (Product storage error).    No concomitant medication information provided. It was reported that in their internal system it kicked back and it said that vaccine was expired 13-Feb-2023. Vaccine was properly stored in the freezer up until the date of administration.  No treatment information provided.
Age: 22.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered, No adverse event
Clinical narrative: No adverse effects; Vaccines was administer 7 days after BUD date; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Vaccines was administer 7 days after date) and NO ADVERSE EVENT (No adverse effects) in a 22-year-old female patient who received mRNA-1273 (Spikevax) (batch no. 015B22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 03-Feb-2023, the patient received first dose of mRNA-1273 (Spikevax) (unknown route) .5 milliliter. On 03-Feb-2023, the patient experienced EXPIRED PRODUCT ADMINISTERED (Vaccines was administer 7 days after BUD date). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse effects). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Vaccines was administer 7 days after date) and NO ADVERSE EVENT (No adverse effects) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse effects) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (Vaccines was administer 7 days after date).    No concomitant medications were reported.     No treatment medications were reported.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Wrong product administered
Clinical narrative: No adverse event; a 52-year-old patient received Monovalent Red Cap Moderna COVID-19 Booster dose on 16FEB2023; This spontaneous case was reported by a pharmacist and describes the occurrence of WRONG PRODUCT ADMINISTERED (a 52-year-old patient received Monovalent Red Cap Moderna COVID-19 Booster dose on 16FEB2023) and NO ADVERSE EVENT (No adverse event) in a 52-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 071B22A) for COVID-19 prophylaxis.     Patient did not received any other vaccines 4 weeks prior to Moderna COVID-19 vaccine.     On 16-Feb-2023, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 16-Feb-2023,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced WRONG PRODUCT ADMINISTERED (a 52-year-old patient received Monovalent Red Cap Moderna COVID-19 Booster dose on 16FEB2023). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, WRONG PRODUCT ADMINISTERED (a 52-year-old patient received Monovalent Red Cap Moderna COVID-19 Booster dose on 16FEB2023) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for WRONG PRODUCT ADMINISTERED (a 52-year-old patient received Monovalent Red Cap Moderna COVID-19 Booster dose on 16FEB2023).    No concomitant medications was reported. No treatment medications was reported.
Sex: U
Vaccine: COVID19-2
Symptoms: Death
Clinical narrative: family member had recently passed; This spontaneous case was reported by a patient family member or friend and describes the occurrence of DEATH (family member had recently passed) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. Death occurred on an unknown date The cause of death was not reported. It is unknown if an autopsy was performed.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter did not provide any causality assessments.   Concomitant medications were not reported.   No treatment information was provided.  Company comment: This spontaneous case reported by a patient family member, concerns an adult patient of unknown gender with no reported medical history, who met with a fatal outcome (PT: Death). Death occurred unknown days after administration of a dose of mRNA-1273.222 bivalent vaccine. Other details are not available for medical review. Exact cause of death was not reported. It is unknown if an autopsy was performed. The benefit-risk relationship of mRNA-1273.222 bivalent vaccine is not affected by this report.    Reporter did not allow further contact; Reported Cause(s) of Death: family member had recently passed
Age: 75.0
Sex: F
Vaccine: COVID19-2
Symptoms: Arthralgia, Vaccination site pain
Clinical narrative: having pain from my shoulder; Two days after receiving the injection in my left arm I started having pain from my shoulder to half way down my upper arm; This spontaneous case was reported by a non-health professional and describes the occurrence of ARTHRALGIA (having pain from my shoulder) and VACCINATION SITE PAIN (Two days after receiving the injection in my left arm I started having pain from my shoulder to half way down my upper arm) in a 75-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. O4H22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 05-Jan-2023, the patient received fourth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular) 1 dosage form. On 07-Jan-2023, the patient experienced ARTHRALGIA (having pain from my shoulder) and VACCINATION SITE PAIN (Two days after receiving the injection in my left arm I started having pain from my shoulder to half way down my upper arm). At the time of the report, ARTHRALGIA (having pain from my shoulder) and VACCINATION SITE PAIN (Two days after receiving the injection in my left arm I started having pain from my shoulder to half way down my upper arm) had not resolved.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported.  It was reported that two days after receiving the injection in left arm patient started having pain from shoulder to half way down upper arm. It has continued to this day. It was unknown if the patient experienced any additional symptoms/events.   No treatment medications were reported.
Sex: U
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event
Clinical narrative: No adverse event; Moderna COVID vaccine given to patient on 2/16/23 that expired on 2/12/23; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Moderna COVID vaccine given to patient on 2/16/23 that expired on 2/12/23) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 015B22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 16-Feb-2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 16-Feb-2023,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced EXPIRED PRODUCT ADMINISTERED (Moderna COVID vaccine given to patient on 2/16/23 that expired on 2/12/23). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Moderna COVID vaccine given to patient on 2/16/23 that expired on 2/12/23) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (Moderna COVID vaccine given to patient on 2/16/23 that expired on 2/12/23).    No concomitant product reported by reporter.  It was unknown if patient received any other vaccines in the 4 weeks prior to COVID-19 vaccine. Moderna COVID vaccine was given to patient on 16-Feb-2023 that expired on 12-Feb-2023 with Lot number 015B22A.  No treatment medication reported by reporter.
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive
Clinical narrative: Pfizer 4/3/21, 4/24/21, 12/29/21. Positive on 2/18/23
Age: 49.0
Sex: F
Vaccine: COVID19-2
Symptoms: COVID-19, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: COVID vaccine breakthrough case
Age: 74.0
Sex: M
Vaccine: COVID19-2
Symptoms: Expired product administered
Clinical narrative: Vaccine Administered after beyond use date (1/28/2023). Staff re-trained on proper storage and handling and process reviewed to ensure safe administration in the future. Moderna contacted regarding administration error for stability information. Patient will be contacted and offered re-vaccination according to CDC recommendations.
Age: 73.0
Sex: F
Vaccine: COVID19-2
Symptoms: Expired product administered
Clinical narrative: Vaccine Administered after beyond use date (1/28/2023). Staff re-trained on proper storage and handling and process reviewed to ensure safe administration in the future. Moderna contacted regarding administration error for stability information. Patient will be contacted and offered re-vaccination according to CDC recommendations.
Age: 71.0
Sex: F
Vaccine: COVID19-2
Symptoms: Medication error, Product storage error
Clinical narrative: Medication error. Vaccine not viable due to improper storage temperature.
Age: 50.0
Sex: F
Vaccine: RAB, TD
Symptoms: Discomfort, Lymph node pain, Lymphadenopathy
Clinical narrative: Left axilla lymph nodes swelled during the night after vaccine on Monday morning and were very painful. Pt reports using a heating pad even though was advised to only use ice for inflammatory response if occurred. Took ibuprofen for continued discomfort. Reports swollen lymph nodes did go away after Saturday morning so lasted 4 days with Wednesday being the worst and then slowly getting better.
Age: 5.0
Sex: F
Vaccine: COVID19
Symptoms: Asthma, Condition aggravated, Croup infectious, Infectious mononucleosis, No adverse event
Clinical narrative: She did not have an adverse reaction to the vaccine. On 10/31/2023 is when her respiratory illnesses started. She had croup first, asthma was flared up; strep throat infection and mono. As of today, she is feeling well.
Age: 5.0
Sex: F
Vaccine: COVID19
Symptoms: Pharyngitis streptococcal, Respiratory disorder
Clinical narrative: She did not have an adverse reaction to the vaccine. On 10/31/2023 is when her respiratory illnesses started. She had croup first, asthma was flared up; strep throat infection and mono. As of today, she is feeling well.
Age: 16.0
Sex: F
Vaccine: MENB
Symptoms: Injection site pain
Clinical narrative: Asked to be given in back side due to patient fear of needles by provider. Given in Left hip area .Pain in area given
Age: 81.0
Sex: M
Vaccine: COVID19-2
Symptoms: Expired product administered
Clinical narrative: Vaccine administered after beyond use date (1/28/23). Staff retrained on proper storage and handling. Process reviewed to ensure safe administration. Moderna contacted regarding the administration error for stability information. Patient will be contacted and offered re-vaccination according to the CDC's recommendation.
Age: 2.0
Sex: F
Vaccine: COVID19
Symptoms: Pruritus, Rash macular, Urticaria
Clinical narrative: On 02/14/2023, 09:30AM, she woke with hives from head to legs. They were on neck, arms, back, belly, legs. She was very itchy. We gave her BENADRYL and put AQUAPHOR all over her. We called my doctor friend and then on Wednesday we started giving her ZYRTEC. On Friday, we went into the clinic. She still gets red splotches morning and night. Wherever she scratches, it turns very red. We are to do ZYRTEC for 30 days and we may move to a steroid if not better.
Age: 62.0
Sex: F
Vaccine: COVID19-2
Symptoms: Cough, Influenza virus test negative, Nasal congestion, Pyrexia, Respiratory tract congestion
Clinical narrative: I had extreme sinus congestion and slight cough, which started on the 17th of January. I used over the counter medicine as directed by doctor until January 29th when I called the doctor and she said it was time for antibiotics. So I went to the Urgent Care and they gave me a z-pack. I took that as prescribed and kept contact with my doctor via system. The infection improved but it was not all gone because I was still stuffy and it came back pretty strong. When I went to bed on the 7th, I was up all night because the congestion was so bad and started having a low grade fever for a few days. On the 8th she prescribed Augmentin and by day 8 of 10 of the medication I felt better. My blood pressure is still a little high, but don't know if it is related. I'm keeping an eye on it and reporting to my doctor.
Age: 62.0
Sex: F
Vaccine: COVID19-2
Symptoms: SARS-CoV-2 test negative, Sinus congestion
Clinical narrative: I had extreme sinus congestion and slight cough, which started on the 17th of January. I used over the counter medicine as directed by doctor until January 29th when I called the doctor and she said it was time for antibiotics. So I went to the Urgent Care and they gave me a z-pack. I took that as prescribed and kept contact with my doctor via system. The infection improved but it was not all gone because I was still stuffy and it came back pretty strong. When I went to bed on the 7th, I was up all night because the congestion was so bad and started having a low grade fever for a few days. On the 8th she prescribed Augmentin and by day 8 of 10 of the medication I felt better. My blood pressure is still a little high, but don't know if it is related. I'm keeping an eye on it and reporting to my doctor.
Age: 80.0
Sex: M
Vaccine: COVID19-2
Symptoms: Expired product administered
Clinical narrative: Vaccine administered after beyond use date (1/28/23). Staff retrained on proper storage and handling. Process reviewed to ensure safe administration. Moderna contacted regarding the administration error for stability information. Patient will be contacted and offered re-vaccination according to the CDC's recommendation.
Age: 71.0
Sex: M
Vaccine: COVID19-2
Symptoms: Medication error, Product storage error
Clinical narrative: Medication error. Vaccine not viable due to improper storage temperature.
Age: 55.0
Sex: F
Vaccine: COVID19-2
Symptoms: COVID-19, Cough, Lymphadenopathy, Pain, Pyrexia
Clinical narrative: I experienced a breakthrough case of COVID-19 with fever, runny nose, body aches, coughing and swollen lymph nodes.
Age: 55.0
Sex: F
Vaccine: COVID19-2
Symptoms: Rhinorrhoea, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: I experienced a breakthrough case of COVID-19 with fever, runny nose, body aches, coughing and swollen lymph nodes.
Age: 77.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive
Clinical narrative: hospitalization
Age: 58.0
Sex: M
Vaccine: COVID19-2
Symptoms: Anticoagulant therapy, Computerised tomogram thorax abnormal, Deep vein thrombosis, Peripheral swelling, Pulmonary thrombosis
Clinical narrative: Fortunately, I was not having chest pains. I went into the emergency for right leg, it was very swollen. They did a CAT scan of my lungs and found that I had blood clots in my lungs. They ordered an ultrasound for my right leg and found that I had DVT. I was then admitted to the hospital. A cardiovascular surgeon was brought in, I did have surgery and was released on Tuesday. I am now giving myself shots of Lovenox twice a day for a while and taking Clopidogrel to help thin my blood to help keep me from getting another blood clot as well as dissolve the ones in my lungs.
Age: 58.0
Sex: M
Vaccine: COVID19-2
Symptoms: Surgery, Ultrasound Doppler abnormal
Clinical narrative: Fortunately, I was not having chest pains. I went into the emergency for right leg, it was very swollen. They did a CAT scan of my lungs and found that I had blood clots in my lungs. They ordered an ultrasound for my right leg and found that I had DVT. I was then admitted to the hospital. A cardiovascular surgeon was brought in, I did have surgery and was released on Tuesday. I am now giving myself shots of Lovenox twice a day for a while and taking Clopidogrel to help thin my blood to help keep me from getting another blood clot as well as dissolve the ones in my lungs.
Age: 62.0
Sex: F
Vaccine: COVID19-2
Symptoms: Medication error, Product storage error
Clinical narrative: Medication error. Vaccine not viable due to improper temperature storage.
Age: 83.0
Sex: F
Vaccine: COVID19-2
Symptoms: COVID-19, Vaccine breakthrough infection
Clinical narrative: Breakthrough COVID
Age: 75.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: COVID-19, Death, SARS-CoV-2 test positive
Clinical narrative: Pt admitted to hospital on 2/12 with covid and pt died on 2/18
Age: 49.0
Sex: F
Vaccine: COVID19-2
Symptoms: Arthralgia, Blood test abnormal, Dry eye, Pain, Pyrexia
Clinical narrative: I started having pain in my ankles that have increased to a continually flashing pain. I had dry eyes, low-grade fever. I went to my doctor who referred me to rheumatologist. She ran blood tests and did x-rays that came back showing that I have factors for rheumatoid arthritis. I will be calling the doctor back to today to confirm the diagnosis and determine if I will be put on medication to combat the pain.
Age: 49.0
Sex: F
Vaccine: COVID19-2
Symptoms: Rheumatoid arthritis, X-ray abnormal
Clinical narrative: I started having pain in my ankles that have increased to a continually flashing pain. I had dry eyes, low-grade fever. I went to my doctor who referred me to rheumatologist. She ran blood tests and did x-rays that came back showing that I have factors for rheumatoid arthritis. I will be calling the doctor back to today to confirm the diagnosis and determine if I will be put on medication to combat the pain.
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Anembryonic gestation, Human chorionic gonadotropin, Maternal exposure before pregnancy, Pregnancy test positive, Ultrasound scan
Clinical narrative: I received both of the Pfizer BioNtech vaccinations.  1 of 2 was given 1/13/2021 and 2of 2 given 2/10/2021.  I have had 2 healthy pregnancies and my husband has had 4 healthy pregnancies.  I received a positive pregnancy test 1/27/2022 and ended up with a blighted ovum and had to have a D&E on 2/24/2022.
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Uterine dilation and evacuation
Clinical narrative: I received both of the Pfizer BioNtech vaccinations.  1 of 2 was given 1/13/2021 and 2of 2 given 2/10/2021.  I have had 2 healthy pregnancies and my husband has had 4 healthy pregnancies.  I received a positive pregnancy test 1/27/2022 and ended up with a blighted ovum and had to have a D&E on 2/24/2022.
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Death, SARS-CoV-2 test positive
Clinical narrative: Death on 02/14/2023
Age: 87.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19-2
Symptoms: Acute respiratory failure, Atelectasis, Blood gases, Blood lactic acid, Body temperature decreased
Clinical narrative: 1/22/2023-Brought in EMS, presents to ED, had been found unresponsive at bottom of stairs. HR in 60, while obtaning CT dropped to 30's, 1 amp Atropine given. Temp-85.8, BP 194/91.Covid + test. Intubated. CT- LArge intraparenchymal Hemmorhage R cerebral hemisphere, centered R temporal and occipital lobes .2x5.9 cm. 1.9cm r to L midline shift. Evidence of impending transtentorial herniation and brainstem deviation to the left. CXR-small desnity upper left lung, atelectasis. Admit to trauma, acute hypoxic resp failure s/t fall, intraparencymal hemorrhage. WBC 18.4 1/23/2023- Vent-AC VC 400/14/100 Fio2/5 Peep. Comfort care patient has been made DNR. Sepsis d/t Covid leukocytosis 18.4, lactic acidosis 2.4. 1/23/2023-Levophed to keep MAP above 65  WBC 13.2. ABG 7.353/43.4/24.1 on 100% Fio2 AC VC vent. 1/24/2023-Terminal exubation @1257.
Age: 87.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19-2
Symptoms: COVID-19, Cerebral haemorrhage, Cerebral mass effect, Chest X-ray abnormal, Computerised tomogram head abnormal
Clinical narrative: 1/22/2023-Brought in EMS, presents to ED, had been found unresponsive at bottom of stairs. HR in 60, while obtaning CT dropped to 30's, 1 amp Atropine given. Temp-85.8, BP 194/91.Covid + test. Intubated. CT- LArge intraparenchymal Hemmorhage R cerebral hemisphere, centered R temporal and occipital lobes .2x5.9 cm. 1.9cm r to L midline shift. Evidence of impending transtentorial herniation and brainstem deviation to the left. CXR-small desnity upper left lung, atelectasis. Admit to trauma, acute hypoxic resp failure s/t fall, intraparencymal hemorrhage. WBC 18.4 1/23/2023- Vent-AC VC 400/14/100 Fio2/5 Peep. Comfort care patient has been made DNR. Sepsis d/t Covid leukocytosis 18.4, lactic acidosis 2.4. 1/23/2023-Levophed to keep MAP above 65  WBC 13.2. ABG 7.353/43.4/24.1 on 100% Fio2 AC VC vent. 1/24/2023-Terminal exubation @1257.
Age: 87.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19-2
Symptoms: Endotracheal intubation, Fall, Fraction of inspired oxygen, Lactic acidosis, Leukocytosis
Clinical narrative: 1/22/2023-Brought in EMS, presents to ED, had been found unresponsive at bottom of stairs. HR in 60, while obtaning CT dropped to 30's, 1 amp Atropine given. Temp-85.8, BP 194/91.Covid + test. Intubated. CT- LArge intraparenchymal Hemmorhage R cerebral hemisphere, centered R temporal and occipital lobes .2x5.9 cm. 1.9cm r to L midline shift. Evidence of impending transtentorial herniation and brainstem deviation to the left. CXR-small desnity upper left lung, atelectasis. Admit to trauma, acute hypoxic resp failure s/t fall, intraparencymal hemorrhage. WBC 18.4 1/23/2023- Vent-AC VC 400/14/100 Fio2/5 Peep. Comfort care patient has been made DNR. Sepsis d/t Covid leukocytosis 18.4, lactic acidosis 2.4. 1/23/2023-Levophed to keep MAP above 65  WBC 13.2. ABG 7.353/43.4/24.1 on 100% Fio2 AC VC vent. 1/24/2023-Terminal exubation @1257.
Age: 87.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19-2
Symptoms: Mechanical ventilation, SARS-CoV-2 test positive, Sepsis, Terminal state, Unresponsive to stimuli
Clinical narrative: 1/22/2023-Brought in EMS, presents to ED, had been found unresponsive at bottom of stairs. HR in 60, while obtaning CT dropped to 30's, 1 amp Atropine given. Temp-85.8, BP 194/91.Covid + test. Intubated. CT- LArge intraparenchymal Hemmorhage R cerebral hemisphere, centered R temporal and occipital lobes .2x5.9 cm. 1.9cm r to L midline shift. Evidence of impending transtentorial herniation and brainstem deviation to the left. CXR-small desnity upper left lung, atelectasis. Admit to trauma, acute hypoxic resp failure s/t fall, intraparencymal hemorrhage. WBC 18.4 1/23/2023- Vent-AC VC 400/14/100 Fio2/5 Peep. Comfort care patient has been made DNR. Sepsis d/t Covid leukocytosis 18.4, lactic acidosis 2.4. 1/23/2023-Levophed to keep MAP above 65  WBC 13.2. ABG 7.353/43.4/24.1 on 100% Fio2 AC VC vent. 1/24/2023-Terminal exubation @1257.
Age: 87.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19-2
Symptoms: White blood cell count increased
Clinical narrative: 1/22/2023-Brought in EMS, presents to ED, had been found unresponsive at bottom of stairs. HR in 60, while obtaning CT dropped to 30's, 1 amp Atropine given. Temp-85.8, BP 194/91.Covid + test. Intubated. CT- LArge intraparenchymal Hemmorhage R cerebral hemisphere, centered R temporal and occipital lobes .2x5.9 cm. 1.9cm r to L midline shift. Evidence of impending transtentorial herniation and brainstem deviation to the left. CXR-small desnity upper left lung, atelectasis. Admit to trauma, acute hypoxic resp failure s/t fall, intraparencymal hemorrhage. WBC 18.4 1/23/2023- Vent-AC VC 400/14/100 Fio2/5 Peep. Comfort care patient has been made DNR. Sepsis d/t Covid leukocytosis 18.4, lactic acidosis 2.4. 1/23/2023-Levophed to keep MAP above 65  WBC 13.2. ABG 7.353/43.4/24.1 on 100% Fio2 AC VC vent. 1/24/2023-Terminal exubation @1257.
Age: 70.0
Sex: M
Vaccine: COVID19
Symptoms: Atrial flutter, Electrocardiogram abnormal
Clinical narrative: Atrial Flutter
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Folliculitis, Pruritus
Clinical narrative: About 3 months after having the vaccine administered, I began having intensive itching on my scalp. These symptoms began in May. I also started taking Tremfya in March of 2022. I thought that the itching was due to scalp psoriasis. I contacted my doctor, and she suggested that I treat it with a steroid shampoo called Clobetasol. I used the shampoo every other day, but my symptoms did not improve. I also developed itching on my back. I treated it with over-the-counter Hydrocortisone cream. It helped but did not make it go away. In August I had a n appointment with a dermatologist for my back and he prescribed a stronger steroid cream called Mometasone. This cream did not get rid of the symptoms. In October I saw a new PCP and told her my story. She prescribed Ketoconnozole cream. I also use Ketoconnozole shampoo, and the symptoms got much better over the 2-to-3-month period. I don't believe my symptoms have resolved. I saw a dermatologist in January 2023, and I was diagnosed with having Folliculitis.
Age: 25.0
Sex: F
Vaccine: COVID19-2
Symptoms: COVID-19, Fatigue, Malaise, Oropharyngeal pain, Respiratory tract congestion
Clinical narrative: I had no adverse reaction to the vaccine. I began not feeling well with congestion, slight sore throat and feeling very tired. I tested positive for COVID-19 on 01/03/2023. I contacted my doctor and did not receive a prescription but asked for advice as to what to do as I am immune compromised. I ended up taking very little as my symptoms where not that bad.
Age: 25.0
Sex: F
Vaccine: COVID19-2
Symptoms: SARS-CoV-2 test positive
Clinical narrative: I had no adverse reaction to the vaccine. I began not feeling well with congestion, slight sore throat and feeling very tired. I tested positive for COVID-19 on 01/03/2023. I contacted my doctor and did not receive a prescription but asked for advice as to what to do as I am immune compromised. I ended up taking very little as my symptoms where not that bad.
Age: 63.0
Sex: F
Vaccine: COVID19-2
Symptoms: Biopsy lung abnormal, Bronchoalveolar lavage abnormal, Bronchoscopy abnormal, COVID-19, Culture positive
Clinical narrative: Discharge Provider:  Primary Care Provider: PA Admission Date: 2/8/2023 Discharge Date: 2/17/23   PRESENTING PROBLEM: Lung transplant status, bilateral  Pneumonia due to infectious organism    HOSPITAL COURSE: Patient was admitted for hypoxia following bronchoscopy on 2/8/23 which was performed due to decline in lung function. Bronchoscopy with significant purulent secretions. Patient initially tested positive for COVID on film array and was started on decadron and remdesivir. Due to purulent secretions on bronch she was started on empiric antibiotics as well. Hypoxia and radiographic findings improved quickly. After near resolution of hypoxia, infiltrates, and symptoms her BAL came back positive for CMV at 10,600. She was started on Valcyte at that time for elevated CMV in BAL. Unclear if this is pneumonitis given resolution of infiltrates and symptoms prior to starting treatment. Additionally she was treated with cefepime x7d for staph/strep that grew on her BAL cultures. Her tbbx came back with A1 as well as organizing pneumonia. Initially planned to treat organizing pneumonia with long steroid taper after decadron for covid treatment was completed, but given multiple other infections, prednisone decreased back to home dose 5mg daily 2/16 with plans for short interval bronchoscopy to re-evaluate and clinic visit to monitor home spirometry. Patient has had persistent leukocytosis in the days preceding discharge but this was thought to be most likely due to steroid burst for covid treatment and day of discharge had started to trend back down. Will monitor as an outpatient. She has also had persistent hyperkalemia which she previously took lokelma daily for prior to admission. This will be resumed upon dc. She will get labs drawn next week with a posaconazole level and follow-up in the clinic in 2 weeks for reassessment.
Age: 63.0
Sex: F
Vaccine: COVID19-2
Symptoms: Cytomegalovirus test positive, Hyperkalaemia, Hypoxia, Increased bronchial secretion, Infection
Clinical narrative: Discharge Provider:  Primary Care Provider: PA Admission Date: 2/8/2023 Discharge Date: 2/17/23   PRESENTING PROBLEM: Lung transplant status, bilateral  Pneumonia due to infectious organism    HOSPITAL COURSE: Patient was admitted for hypoxia following bronchoscopy on 2/8/23 which was performed due to decline in lung function. Bronchoscopy with significant purulent secretions. Patient initially tested positive for COVID on film array and was started on decadron and remdesivir. Due to purulent secretions on bronch she was started on empiric antibiotics as well. Hypoxia and radiographic findings improved quickly. After near resolution of hypoxia, infiltrates, and symptoms her BAL came back positive for CMV at 10,600. She was started on Valcyte at that time for elevated CMV in BAL. Unclear if this is pneumonitis given resolution of infiltrates and symptoms prior to starting treatment. Additionally she was treated with cefepime x7d for staph/strep that grew on her BAL cultures. Her tbbx came back with A1 as well as organizing pneumonia. Initially planned to treat organizing pneumonia with long steroid taper after decadron for covid treatment was completed, but given multiple other infections, prednisone decreased back to home dose 5mg daily 2/16 with plans for short interval bronchoscopy to re-evaluate and clinic visit to monitor home spirometry. Patient has had persistent leukocytosis in the days preceding discharge but this was thought to be most likely due to steroid burst for covid treatment and day of discharge had started to trend back down. Will monitor as an outpatient. She has also had persistent hyperkalemia which she previously took lokelma daily for prior to admission. This will be resumed upon dc. She will get labs drawn next week with a posaconazole level and follow-up in the clinic in 2 weeks for reassessment.
Age: 63.0
Sex: F
Vaccine: COVID19-2
Symptoms: Leukocytosis, Lung infiltration, Lung transplant, Organising pneumonia, Pneumonia
Clinical narrative: Discharge Provider:  Primary Care Provider: PA Admission Date: 2/8/2023 Discharge Date: 2/17/23   PRESENTING PROBLEM: Lung transplant status, bilateral  Pneumonia due to infectious organism    HOSPITAL COURSE: Patient was admitted for hypoxia following bronchoscopy on 2/8/23 which was performed due to decline in lung function. Bronchoscopy with significant purulent secretions. Patient initially tested positive for COVID on film array and was started on decadron and remdesivir. Due to purulent secretions on bronch she was started on empiric antibiotics as well. Hypoxia and radiographic findings improved quickly. After near resolution of hypoxia, infiltrates, and symptoms her BAL came back positive for CMV at 10,600. She was started on Valcyte at that time for elevated CMV in BAL. Unclear if this is pneumonitis given resolution of infiltrates and symptoms prior to starting treatment. Additionally she was treated with cefepime x7d for staph/strep that grew on her BAL cultures. Her tbbx came back with A1 as well as organizing pneumonia. Initially planned to treat organizing pneumonia with long steroid taper after decadron for covid treatment was completed, but given multiple other infections, prednisone decreased back to home dose 5mg daily 2/16 with plans for short interval bronchoscopy to re-evaluate and clinic visit to monitor home spirometry. Patient has had persistent leukocytosis in the days preceding discharge but this was thought to be most likely due to steroid burst for covid treatment and day of discharge had started to trend back down. Will monitor as an outpatient. She has also had persistent hyperkalemia which she previously took lokelma daily for prior to admission. This will be resumed upon dc. She will get labs drawn next week with a posaconazole level and follow-up in the clinic in 2 weeks for reassessment.
Age: 63.0
Sex: F
Vaccine: COVID19-2
Symptoms: Pulmonary function test decreased, Purulent discharge, Respiratory symptom, SARS-CoV-2 test positive, Staphylococcus test positive
Clinical narrative: Discharge Provider:  Primary Care Provider: PA Admission Date: 2/8/2023 Discharge Date: 2/17/23   PRESENTING PROBLEM: Lung transplant status, bilateral  Pneumonia due to infectious organism    HOSPITAL COURSE: Patient was admitted for hypoxia following bronchoscopy on 2/8/23 which was performed due to decline in lung function. Bronchoscopy with significant purulent secretions. Patient initially tested positive for COVID on film array and was started on decadron and remdesivir. Due to purulent secretions on bronch she was started on empiric antibiotics as well. Hypoxia and radiographic findings improved quickly. After near resolution of hypoxia, infiltrates, and symptoms her BAL came back positive for CMV at 10,600. She was started on Valcyte at that time for elevated CMV in BAL. Unclear if this is pneumonitis given resolution of infiltrates and symptoms prior to starting treatment. Additionally she was treated with cefepime x7d for staph/strep that grew on her BAL cultures. Her tbbx came back with A1 as well as organizing pneumonia. Initially planned to treat organizing pneumonia with long steroid taper after decadron for covid treatment was completed, but given multiple other infections, prednisone decreased back to home dose 5mg daily 2/16 with plans for short interval bronchoscopy to re-evaluate and clinic visit to monitor home spirometry. Patient has had persistent leukocytosis in the days preceding discharge but this was thought to be most likely due to steroid burst for covid treatment and day of discharge had started to trend back down. Will monitor as an outpatient. She has also had persistent hyperkalemia which she previously took lokelma daily for prior to admission. This will be resumed upon dc. She will get labs drawn next week with a posaconazole level and follow-up in the clinic in 2 weeks for reassessment.
Age: 63.0
Sex: F
Vaccine: COVID19-2
Symptoms: Streptococcus test positive
Clinical narrative: Discharge Provider:  Primary Care Provider: PA Admission Date: 2/8/2023 Discharge Date: 2/17/23   PRESENTING PROBLEM: Lung transplant status, bilateral  Pneumonia due to infectious organism    HOSPITAL COURSE: Patient was admitted for hypoxia following bronchoscopy on 2/8/23 which was performed due to decline in lung function. Bronchoscopy with significant purulent secretions. Patient initially tested positive for COVID on film array and was started on decadron and remdesivir. Due to purulent secretions on bronch she was started on empiric antibiotics as well. Hypoxia and radiographic findings improved quickly. After near resolution of hypoxia, infiltrates, and symptoms her BAL came back positive for CMV at 10,600. She was started on Valcyte at that time for elevated CMV in BAL. Unclear if this is pneumonitis given resolution of infiltrates and symptoms prior to starting treatment. Additionally she was treated with cefepime x7d for staph/strep that grew on her BAL cultures. Her tbbx came back with A1 as well as organizing pneumonia. Initially planned to treat organizing pneumonia with long steroid taper after decadron for covid treatment was completed, but given multiple other infections, prednisone decreased back to home dose 5mg daily 2/16 with plans for short interval bronchoscopy to re-evaluate and clinic visit to monitor home spirometry. Patient has had persistent leukocytosis in the days preceding discharge but this was thought to be most likely due to steroid burst for covid treatment and day of discharge had started to trend back down. Will monitor as an outpatient. She has also had persistent hyperkalemia which she previously took lokelma daily for prior to admission. This will be resumed upon dc. She will get labs drawn next week with a posaconazole level and follow-up in the clinic in 2 weeks for reassessment.
Age: 50.0
Sex: M
Vaccine: COVID19
Symptoms: Bronchial hyperreactivity, COVID-19, Cough, Fatigue, Influenza virus test negative
Clinical narrative: On Dec 22 went in to PCP for persistent cough due to having reactive airway disorder. Doctor performed Flu; COVID-19; and RSV. Was prescribed a steroid and cough suppressant. Nurse called me an hour later and told me I had tested positive for COVID-19. Was told to isolate and proceed with medications I had already been prescribed. Congestion continued for 10 days, cough continued for 15 days, and fatigue lasted about a month.  Medications prescribed did help manage symptoms.
Age: 50.0
Sex: M
Vaccine: COVID19
Symptoms: Respiratory syncytial virus test negative, Respiratory tract congestion, SARS-CoV-2 test positive
Clinical narrative: On Dec 22 went in to PCP for persistent cough due to having reactive airway disorder. Doctor performed Flu; COVID-19; and RSV. Was prescribed a steroid and cough suppressant. Nurse called me an hour later and told me I had tested positive for COVID-19. Was told to isolate and proceed with medications I had already been prescribed. Congestion continued for 10 days, cough continued for 15 days, and fatigue lasted about a month.  Medications prescribed did help manage symptoms.
Age: 81.0
Sex: F
Vaccine: COVID19-2
Symptoms: Incorrect product formulation administered
Clinical narrative: A dose of Pfizer bivalent was given for a 2nd dose of the primary series instead of a dose of Pfizer monovalent.
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Feeding disorder, Feeling abnormal, Impaired work ability, Influenza like illness
Clinical narrative: I felt really bad, very achy, had a temperature, felt like I had the flu. I had to take two days off from work could not get out of bed, nausea, could not eat. I took a home a COVID-19 test that came back negative. I made an appointment with my pulmonologist, had x-rays done. He determined that I have long COVID-19 from when I did have COVID-19. I have an appointment scheduled with my primary care physician to be tested for cancer as my sister has now tested positive and getting treated for cancer.